APOTEX CORP. for APOTEX CORP.
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Manufacturing MAN
S. 4683, the National Defense Authorization Act for Fiscal Year 2025, Section 887, Requirement to produce domestically produced generic drugs, provisions relating to requiring the Department of Defense to purchase domestically manufactured generic drugs and use active pharmaceutical ingredients and key starting materials sourced domestically or from eligible countries; and Federal policy relating to providing incentives to spur domestic manufacturing of generic drugs.
Foreign entity interest: Apotex Corp., in its 4Q 2024 Form LD-2, delisted all previously disclosed Foreign Entities following the purchase of Apotex Corp. and its direct and indirect parent corporations and affiliates by a domestic US company. Apotex Inc. exercises management over Apotex Corp. but holds no equity in, and provides no funding of, Apotex Corp. lobbying activities. Apotex Inc.'s interest in Apotex Corp. lobbying activities is limited to Apotex Corp.'s commercial and financial success.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Health Issues HCR
Federal policy relating to addressing drug shortages and strengthening pharmaceutical supply chains through partnerships with North American and other allied countries; Draft Senate Finance Committee drug shortage legislation (no bill number), provisions relating to Medicare reimbursement policies for generic drugs; Federal policy relating to the implementation of a pharmaceutical manufacturer reliability rating system and incentives in the Medicare program for providers to purchase generic drugs from manufacturers with higher reliability ratings; S. 5573, The Skinny Label Big Savings Act, provisions relating to creating a safe harbor for the use of the skinny labeling pathway for generic pharmaceuticals and biosimilars.
Foreign entity interest: Apotex Corp., in its 4Q 2024 Form LD-2, delisted all previously disclosed Foreign Entities following the purchase of Apotex Corp. and its direct and indirect parent corporations and affiliates by a domestic US company. Apotex Inc. exercises management over Apotex Corp. but holds no equity in, and provides no funding of, Apotex Corp. lobbying activities. Apotex Inc.'s interest in Apotex Corp. lobbying activities is limited to Apotex Corp.'s financial success in the US market.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Foreign entities
Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.
| Entity | Country | Principal place of business | Ownership | Contribution declared |
|---|---|---|---|---|
| APOTEX INC. | Canada | Canada | — | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.